Abstract
Background: We first reported that interferon (IFN) prevent hepatocarcinogenesis in patients with chronic active hepatitis C with cirrhosis in 1995. However, even in the patients who achieved sustained viral response, some patients developed hepatocellular carcinoma (HCC). In these patients, IFN therapy decreased the incidence of recurrence after resection of HCC. In this study, we evaluated the effects of post-operative interferon therapy on the recurrence and the survival rate after resection of HCC.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kubo S, Nishiguchi S, Shuto T, Tanaka H, Tsukamoto T, Hirohashi K, et al. Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. Jpn J Cancer Res 1999;90:162–70.
Kubo S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Ikebe T, et al. Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. World J Surg 2000;24:1559–65.
Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051–5.
Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al. Effects of long-term postoperative interferon-a on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: a randomized, controlled trial. Ann Inter Med 2001;134:963–7.
Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196–7.
Takenaka K, Yamamoto K, Taketomi A, Itasaka H, Adachi E, Shirabe K, et al. A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology 1995;22:20–4.
Pugh RNH, Murray-Lyon HO, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646–9.
Kubo S, Nishiguchi S, Hirohashi K, Shuto T, Kuroki T, Minamitani S, et al. Clinicopathological criteria for multicentricity of hepatocellular carcinoma and risk factors for such carcinogenesis. Jpn J Cancer Res 1998;89:419–26.
Kubo S, Yamamoto T, Ikebe T, Shuto T, Hirohashi K, Tanaka H, et al. Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C. Jpn J Cancer Res 1999;90:1076–80.
Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174–81.
Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517–24.
Dunk AA, Ikeda T, Pignatelli M, Thomas HC. Human lymphoblastoid interferon: in vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 1986;2:419–29.
Baron S, Tyring Sk, Fleischmann WR, Coppenhauer DH, Niesel DW, Klimper GR. The interferons. Mechanisms of action and clinical applications. JAMA 1991;266:1375–83.
Sing RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferon-a and ß down regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995;92:4562–6.
Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon-beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228–32.
Lai C-L, Lau JYN, Wu P-C, Ngan H, Chung H-T, Mitchell SJ, et al. Recombinant interferon-a in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;13:389–94.
Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996;111:720–6.
Hirohashi K, Shuto T, Kubo S, Tanaka H, Yamamoto T, Ikebe T, et al. Prognostic factors after recurrence of resected hepatocellular carcinoma associated with hepatitis C virus. J Hepatobiliary Pancreat Surg 2001;8:81–6.
Serfaty L, Aumaître H, Chazouillères O, Bonnand A-M, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435–40.
Desmet V, Gerber M, Hoofnagle J, Manns M, Scheuer P. Classification of chronic hepatitis diagnosis, grading and staging. Hepatology 1994;19:1513–20.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Japan
About this paper
Cite this paper
Nishiguchi, S., Kubo, S. (2004). Randomized Trial of Post-Operative Interferon Therapy After Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma and Long-Term Outcome. In: Omata, M., Okita, K. (eds) Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma. Springer, Tokyo. https://doi.org/10.1007/978-4-431-53977-3_20
Download citation
DOI: https://doi.org/10.1007/978-4-431-53977-3_20
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-67975-2
Online ISBN: 978-4-431-53977-3
eBook Packages: Springer Book Archive